KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) EBIT Margin (2016 - 2025)

Alnylam Pharmaceuticals' EBIT Margin history spans 16 years, with the latest figure at 12.01% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 2974.0% year-over-year to 12.01%; the TTM value through Dec 2025 reached 15.92%, up 2379.0%, while the annual FY2025 figure was 13.51%, 2137.0% up from the prior year.
  • EBIT Margin reached 12.01% in Q4 2025 per ALNY's latest filing, down from 29.46% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 60.26% in Q1 2025 to a low of 104.89% in Q1 2021.
  • Average EBIT Margin over 5 years is 35.16%, with a median of 36.7% recorded in 2023.
  • Peak YoY movement for EBIT Margin: surged 12612bps in 2023, then crashed -4385bps in 2024.
  • A 5-year view of EBIT Margin shows it stood at 75.26% in 2021, then grew by 25bps to 56.3% in 2022, then skyrocketed by 53bps to 26.47% in 2023, then skyrocketed by 33bps to 17.73% in 2024, then surged by 168bps to 12.01% in 2025.
  • Per Business Quant, the three most recent readings for ALNY's EBIT Margin are 12.01% (Q4 2025), 29.46% (Q3 2025), and 2.09% (Q2 2025).